1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Revised October 2000). WHO Web site .http://www.who.int/mediacentre/ factsheets/fs204 /en/ in html
2. Visvanathan K, Lewin SR. Immuno-pathogenesis: Role of innate and adaptive immune responses. Semin Liver Dis, 2006;26(2):104-115
3. De Franchis R, Hadengue A, Lau G, et al. EASL international consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland.Consensus statement (long version). J Hepatol, 2003;39(suppl 1):S3-25
4. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南. 2005年
5. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infection Diseases, 2001; 2: 43-50
6. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol, 2007; 85: 16-23
7. Zonneveld MV, Honkoop P, Hansen BE, et al. Long-term follow-up alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004; 39: 804-810
8. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med, 1993; 119(4): 312-323等 北京地坛医院传染病研究所 成军